Infliximab is an intravenously administered selective immunosuppressive and anti-inflammatory TNF‐α inhibitor used to treat rheumatoid and psoriatic arthritis, Crohn’s disease, and ankylosing spondylitis. The gene discussed is TNF; the disease is Crohn disease.